Nanolattix Attends 10th Guangzhou (Greater Bay Area) Biopharma Innovation Summit, Shares Advancements in ADC and RDC Therapeutics
Release time:
2025-11-11
November 6, 2025, Guangzhou – The 10th Guangzhou (Greater Bay Area) Biopharma Innovation Summit (NDC2025) was grandly convened. Nanolattix was invited to attend, during which Ms. Deng Yingmin, Secretary to the Chairman, delivered a themed speech titled "Innovation of Novel Antibody-Drug Conjugate ADC/RDC Anti-Cancer Drugs," sharing Nanolattix's cutting-edge achievements and practical experience across multiple dimensions including technological innovation and strategic layout in the ADC and RDC fields.
In her speech, Ms. Deng highlighted the R&D progress of several investigational drugs, including the ADC candidate T320 and the RDC candidate RT01, which Nanolattix is actively advancing based on its self-developed BioLattix technology platform. The company's core drug, T320-ADC, is currently undergoing global multi-center clinical trials, and has demonstrated positive outcomes with observed Stable Disease (SD) in cervical cancer patients. By leveraging the synergy between ADC and RDC conjugate technologies, Nanolattix is building an integrated solution spanning from precise diagnosis to efficient treatment, aiming to provide new strategies for reducing the risks of tumor drug resistance and recurrence. This presentation garnered significant interest from the attendees.
Through this summit, Nanolattix comprehensively demonstrated its integrated capabilities in the field of complex conjugate drugs, ranging from technological exploration to industrialization. The company looks forward to using this opportunity to deepen communication and collaboration with industry partners in the biopharmaceutical sector, jointly driving the research, development, and breakthrough of innovative anti-cancer drugs.
Tag:
recommend News
Share
